Item Details
Sino Biopharma Signs US$358 Million Drug Licensing Deal
On 6 November, Sino Biopharmaceutical announced a deal with Boehringer Ingelheim worth US$358 million upfront, with potential milestone and option payments of up to US$7 billion, plus royalties. HPC can support pharmaceutical investment research and strategic introductions.
Get in Touch
We’ll get back to you shortly.